SOUTH
SAN FRANCISCO, Calif., Feb. 1, 2023
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
synthetic lethality focused precision medicine oncology company
committed to the discovery and development of targeted
therapeutics, announced its participation in the 2023 Guggenheim
Oncology Conference.
2023 Guggenheim Oncology Conference
Thursday, February 9, 2023 at
7:45 AM PT (10:45 AM ET)
Fireside chat with Yujiro S. Hata, President and Chief Executive
Officer and Michael White, Senior
Vice President and Chief Scientific Officer, hosted by Charles Zhu, Ph.D. Vice President and Equity
Research Analyst
A live audio webcast of the event will be available, as
permitted by conference host, at the "Investors/ Events" section of
the IDEAYA website at https://ir.ideayabio.com/events. A
replay of the webcast will be accessible for 30 days following the
live event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's
Quarterly Report on Form 10-Q filed on November 8, 2022 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-the-2023-guggenheim-oncology-conference-301735419.html
SOURCE IDEAYA Biosciences, Inc.